These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14964752)

  • 21. Secukinumab retreatment associated psoriasis flare with pustules.
    El-Komy M; Amer M; Mostafa A; ElKalioby M
    J Dermatolog Treat; 2022 Mar; 33(2):1107-1110. PubMed ID: 32538223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
    Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
    J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment.
    Brenner M; Molin S; Ruebsam K; Weisenseel P; Ruzicka T; Prinz JC
    Br J Dermatol; 2009 Oct; 161(4):964-6. PubMed ID: 19681858
    [No Abstract]   [Full Text] [Related]  

  • 24. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
    Myers WA; Najarian D; Gottlieb AB
    J Dermatolog Treat; 2006; 17(6):353-4. PubMed ID: 17853308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
    Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
    J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of Patients with Generalized Pustular Psoriasis and Psoriatic Arthritis: A Retrospective Cohort Study.
    Manome-Zenke Y; Ohara Y; Fukui S; Kobayashi D; Sugiura K; Ikeda S; Arai S
    Acta Derm Venereol; 2022 Apr; 102():adv00685. PubMed ID: 35312017
    [No Abstract]   [Full Text] [Related]  

  • 28. Current concepts and review of efalizumab in the treatment of psoriasis.
    Leonardi CL
    Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR; Emer J
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
    Gisondi P; Giglio MD; Girolomoni G
    J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of recurrent cutaneous abscesses during therapy with infliximab.
    De Simone C; Murri R; Maiorino A; Venier A; Caldarola G
    Clin Ther; 2011 Dec; 33(12):1993-6. PubMed ID: 22088412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
    Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Picture of the month--quiz case. Pustular psoriasis, annular type.
    Chang L; Ubriani R; Yan AC
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):989-90. PubMed ID: 18838653
    [No Abstract]   [Full Text] [Related]  

  • 37. Secukinumab-induced paradoxical pustular psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Clin Exp Dermatol; 2019 Jan; 44(1):72-73. PubMed ID: 30129214
    [No Abstract]   [Full Text] [Related]  

  • 38. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
    Kop EN; Körver JE; Van Ruysevelt D; De Jong EM; Van der Valk PG; Van de Kerkhof PC
    J Dermatolog Treat; 2009; 20(1):67-9. PubMed ID: 18651300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pustular psoriasis induced by terbinafine : differential diagnosis from acute generalized exanthematous pustulosis.
    Tokuyama Y; Senoh A; Setsu N; Iwatsuki K
    Eur J Dermatol; 2008; 18(6):725-6. PubMed ID: 19049946
    [No Abstract]   [Full Text] [Related]  

  • 40. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents.
    Adişen E; Karaca F; Gürer MA
    Clin Exp Dermatol; 2008 Mar; 33(2):164-6. PubMed ID: 18257837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.